Navigation Links
Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
Date:10/22/2010

BEIJING, Oct. 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company's Board of Directors has accepted the resignation of Dr. Ian Ashley from the Board.

Chairman and CEO Mr. Zhongyi Liu stated, "Dr. Ashley has served as a valued member of the Board for four years, and we sincerely appreciate his service. We are preparing to apply for a listing on a national securities exchange and are adding experienced directors who will be actively involved in guiding the Company."

The Company's management also reaffirms its previously issued guidance of $73.6 million in revenues and $21.4 million in net income for fiscal 2010. Management is confident in the Company's performance for the rest of the year and looks forward to updating investors on Lotus' third quarter results in the 10-Q filing and earnings release, which are scheduled to be released on or before Monday, November 15.

Lotus' management team will also be traveling to multiple cities in the U.S. to meet with brokers and institutional investors in early November. The circuit will involve meetings and presentations in San Francisco, Los Angeles, Phoenix, Chicago, and New York between Thursday, November 4 and Tuesday, November 9. Financial professionals who are interested in meeting with Lotus' management can contact Jon Cunningham at (407) 644-4256, Ext. 107 or Jon@redchip.com.

About Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drug stores in 30 provinces of the PRC.

Information Regarding Forward-Looking StatementsExcept for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.Contacts:At the Company:Xing Shen, Ph.D.VP of Corporate DevelopmentLotus Pharmaceuticals, Inc.Ph: 415-690-7688Email: shen@lotuspharma.comWeb: http://www.lotuspharma.comInvestor Relations:Jon CunninghamRedChip Companies, Inc.Tel: +1-800-733-2447, Ext. 107Email: info@redchip.comJing Zhang, ChinaRedChip Beijing Representative OfficeTel: +86 10-8591-0635Web: http://www.RedChip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
2. Lotus Pharmaceuticals Announces Two Senior Management Appointments
3. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
4. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
5. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
6. Lotus Completed R-Bambuterols Pilot Scale Production for Clinical Trials
7. Lotus Pharmaceuticals Terminates SEDA
8. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
9. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
10. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
11. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
(Date:4/27/2016)... April 27, 2016  Bayer Animal Health today ... from the University of Florida College of Veterinary ... Excellence in Communication Award (BECA). Brittany was selected ... awarded a total of $70,000 in scholarship funds ... years, Bayer has provided a total of $232,500 ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive ... to announce one of their physicians has been invited to be a featured speaker ... Family Practice Review conference on April 30, 2016. , Dr. R. Scott McPherson, ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader in ... by Eastside Partners, with participation from existing investor Martin Ventures. The funds ... its technology and product roadmap. , “Jvion is experiencing significant growth ...
(Date:4/29/2016)... ... 29, 2016 , ... Nike Softball Camp at the College of Brockport in ... for girls aged 10-18. All facets of the game will be covered; hitting, fielding, ... Complex, one of the finest softball facilities in the region. The outstanding professional college ...
Breaking Medicine News(10 mins):